Infusion
Real-world ublituximab for MS demonstrates similar clinical benefits as in phase 3 studies
WEST PALM BEACH, Fla. — Real-world effects of ublituximab after 1 year of administration were consistent with data from a pair of phase 3 clinical trials investigating the drug, according to a poster presented at ACTRIMS.
High dose of novel PD gene therapy linked to improved outcomes at 26 weeks
Topline data from a phase 2 clinical trial of an investigational gene therapy for Parkinson’s disease showed that a higher dose of the medication significantly improved disease-specific and quality of life measures by week 26.
‘Likely clinically important benefit’ with continuous beta-lactam antibiotic infusions
More ICU patients with sepsis receiving a continuous vs. intermittent infusion of beta-lactam antibiotics achieved clinical cure by day 14, but 90-day mortality was similar, according to research published in JAMA.
Changes in infusion drug insurance coverage jeopardize ‘hard-won’ disease control
An increasing number of insurance carriers are cutting out infusion centers and small practices for the delivery of infusion medications, and the impact on patient care could be profound.
Fresenius Kabi recalls Ivenix Infusion System software over ‘anomalies’
Large volume infusion pump software related to the Ivenix Infusion System has been recalled by its manufacturer due to multiple potentially dangerous issues, according to a press release from the FDA.
Sedation with dexmedetomidine, increasing propofol dose lowers mortality in younger adults
A constant dexmedetomidine dose paired with an increasing propofol dose lowered the risk for mortality in ICU patients aged 65 years or younger, according to results published in American Journal of Respiratory and Critical Care Medicine.
Continuous subcutaneous apomorphine infusion reduces motor fluctuations in PD
CHICAGO — Continuous subcutaneous apomorphine infusion reduced “off” time and increased “on” time without troublesome dyskinesia in patients with Parkinson’s disease in the United States, with no new safety signals reported.
Fresenius Kabi recalls Ivenix Infusion System over leaks that delay, interrupt therapy
The Ivenix Infusion System has been recalled by its manufacturer due to a system leak that may compromise the ability of the equipment to properly deliver infusions, according to press release from the FDA.
Most staff who deliver home infusion therapy not trained in infection surveillance
There has been a significant increase in the number of people receiving home infusion therapy over the last decade, but a study found that many who deliver these services have no formal training in infection surveillance.
Gene therapy restores immunity in Artemis-deficient severe combined immunodeficiency
Infants with Artemis-deficient severe combined immunodeficiency improved after corrected genes in their stem cells enabled them to grow their own T cells and B cells, according to a study published in The New England Journal of Medicine.